Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Fasoracetam | Ginkgo Biloba | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 20-100 mg 1-3 times daily (sublingual or oral) | 120-240 mg/day of standardized extract (24% flavone glycosides, 6% terpene lactones) divided into 2-3 doses |
| Timing | Morning and afternoon. Sublingual administration may provide faster onset and higher bioavailability. With or without food. | With or without food. Split into 2-3 doses throughout the day. Effects may take 4-6 weeks to manifest. |
| Cycle Duration | Cycles of 4-8 weeks on, 2-4 weeks off. Limited long-term safety data. | Ongoing; no cycling required. Clinical trials typically run 22-26 weeks. |
| Evidence Level | animal_plus_anecdotal | strong_human |
Non-classical racetam that modulates all three groups of metabotropic glutamate receptors (mGluR Groups I, II, and III) and upregulates GABA-B receptors — a unique mechanism that distinguishes it from other racetams. Also enhances high-affinity choline uptake (HACU) and stimulates acetylcholine release. Does not significantly affect adrenergic, serotonergic, or dopaminergic receptors. The GABA-B upregulation is particularly notable as it may counteract GABA-B receptor downregulation caused by phenibut or baclofen tolerance.
20-100 mg 1-3 times daily (sublingual or oral)
Morning and afternoon. Sublingual administration may provide faster onset and higher bioavailability. With or without food.
Cycles of 4-8 weeks on, 2-4 weeks off. Limited long-term safety data.
Standardized extract (EGb 761) contains flavonoid glycosides (24%) and terpene lactones (6% — ginkgolides A/B/C and bilobalide) that act through multiple pathways: potent free radical scavenging and inhibition of membrane lipid peroxidation; antagonism of platelet-activating factor (PAF) via ginkgolides; enhancement of cerebral blood flow through nitric oxide-mediated vasodilation and reduced blood viscosity; and increased prefrontal dopamine and acetylcholine release via acylated flavonol glycosides. Bilobalide provides direct neuroprotection against excitotoxicity and mitochondrial dysfunction.
120-240 mg/day of standardized extract (24% flavone glycosides, 6% terpene lactones) divided into 2-3 doses
With or without food. Split into 2-3 doses throughout the day. Effects may take 4-6 weeks to manifest.
Ongoing; no cycling required. Clinical trials typically run 22-26 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →